CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 6, 2008
Result type: Reports
Project Number: SR0127-000
Product Line: Reimbursement Review

Generic Name: Daptomycin

Brand Name: Cubicin

Manufacturer: Cubist Pharmaceuticals Inc.

Therapeutic Area: Skin and skin structure infections & bacteremia

Indications: Skin and skin structure infections & bacteremia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 24, 2008

Recommendation Type: Do not list